PharmaShots | Incisive News in 3 Shots

Subscribe Now

Relapsed or Refractory Mantle Cell Lymphoma

$Kite's Tecartus (brexucabtagene autoleucel) Receives Health Canada's Approval for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma$

Kite's Tecartus (brexucabtagene autoleucel) Receives Health Canada's Approval for the Treatment of Relapsed or Refractory Mantle C...

October 29, 2021

Kite's Tecartus (KTE-X19) Receives EC's Conditional Marketing Authorization for R/R Mantle Cell Lymphoma

Kite's Tecartus (KTE-X19) Receives EC's Conditional Marketing Authorization for R/R Mantle Cell Lymphoma

December 17, 2020

AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL

AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL

December 7, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us